The effect of quetiapine (Seroquel™) on conditioned place preference and elevated plus maze tests in rats when administered alone and in combination with (+)-amphetamine

Psychopharmacology

Volumn 231, Issue 22, 2014, Pages 4349-4359

  McLelland, Angela E ^a,b   Martin Iverson, Mathew T ^b   Beninger, Richard J ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

(+) Amphetamine; Anxiety; Conditioned place preference; Elevated plus maze; Quetiapine; Reward

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; QUETIAPINE;

ANIMAL; ANIMAL BEHAVIOR; ANXIETY; CONDITIONING; DRUG EFFECTS; DRUG POTENTIATION; MALE; MAZE TEST; RAT; REWARD; WISTAR RAT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING (PSYCHOLOGY); DIBENZOTHIAZEPINES; DRUG SYNERGISM; MALE; MAZE LEARNING; RATS; RATS, WISTAR; REWARD;

EID: 84939881939     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3578-2     Document Type: Article

References (54)

1. Ashton CH (2002). Benzodiazepine use. http://www.benzo.org.uk/ashbzab.htm. Accessed 9 Aug 2012
2. Beninger RJ, Miller R (1998) Dopamine D1-like receptors and reward-related incentive learning. Neurosci Biobehav Rev 22:335-345
3. Beninger RJ, Baker TW, Florczynski MM, Banasikowski T (2010) Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients. Neurotox Res 18:229-243. doi: 10.1007/s12640-010-9178-y
4. Burnette WB, Bailey MD, Kukoyi S, Blakely RD, Trowbridge CG, Justice JB Jr (1996) Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem 68:2932-2938
5. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
6. Che S-SA, Menard JL (2011) Lesions of the dorsal lateral septum do not affect neophagia in the novelty induce suppression of feeding paradigm but reduce defensive behaviours in the elevated plus maze and shock probe burying tests. Behav Brain Res 220:362-366. doi: 10.1016/j.bbr.2011.02.027
7. Christensen RC, Garces LK (2006) The growing abuse of commonly prescribed psychiatric medications. Am J Emerg Med 24:137-138
8. Crespi D, Mennini T, Gobbi M (1997) Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735-1743
9. Dringenberg HC, de Souza-Silva MA, Schwarting RK, Huston JP (1998) Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Naunyn Schmiedeberg's Arch Pharmacol 358:423-429
10. Druid H, Holmgren P, Ahlner J (2001) Flunitrazepam: an evaluation of use, abuse and toxicity. Forensic Sci Int 122:136-141
11. Erowid (2007) Erowid experience vaults. Amphetamine and benzodiazepine synergy. http://www.erowid.org/experiences/exp.php?ID=18396. Accessed 9 Aug 2012
12. Fischer BA, Boggs DL (2010) The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature. Neurosci Biobehav Rev 34:555-558. doi: 10.1016/j.neubiorev.2009.11.003
13. Fleckenstein AE, Gibb JW, Hanson GR (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406:1-13
14. Gallo A, Lapointe S, Stip E, Potvin S, Rompre PP (2010) Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behav Brain Res 208:163-168. doi: 10.1016/j.bbr.2009.11.029
15. Gao K, Sheehan DV, Calabrese JR (2009) Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 9:1147-1158
16. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 112:293-298
17. He J, Xu H, Yang Y, Zhang X, Li X (2005) Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav Brain Res 160:178-187
18. Hoffman DC, Beninger RJ (1989) The effects of selective dopamine D1 or D2 receptor antagonists on the establishment of agonist-induced place conditioning in rats. Pharmacol Biochem Behav 33:273-279
19. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-Deskalkylquetiapine, a potent norepinephrine reuptake inhibitior and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312
20. Jones HM, Travis MJ, Mulligan R, Bressan RA, Visvikis D, Gacinovic S, Ell PJ, Pilowsky LS (2001) In vivo 5-HT2A receptor blockade by quetiapine. An R91150 single photon emission tomography study. Psychopharmacology 157:60-66
21. Kasper S, Tauscher J, Heiden A (2001) Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 11:S405-S413
22. Keming G, Sheehan DV, Calabrese JR (2009) Quetiapine has established anxiolytic effects in people (atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Exp Rev Neurother 9:1147-1158. doi: 10.1586/ern.09.37
23. Kosten TA, Nestler EJ (1994) Clozapine attenuates cocaine conditioned place preference. Life Sci 55:9-14
24. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
25. Lin HQ, Burden PM, Christie MJ, Johnston GAR (1999) The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav 62:403-408
26. Martin-Iverson MT, Ortmann R, Fibiger HC (1985) Place preference conditioning with methylphenidate and nomifensine. Brain Res 332:59-67
27. Matsui A, Matsuo H, Takanaga H, Sasaki S, Maeda M, Sawada Y (1998) Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. J Pharmacol Exp Ther 287:725-732
28. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ (2009) A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacol 8:1211-1219
29. Mechanic JA, Maynard BT, Holloway FA (2003) Treatment with the atypical antipsychotic, olanzapine, prevents the expression of amphetamine-induced place conditioning in the rat. Prog Neuro-Psychopharmacol 27:43-54
30. Mithani S, Martin-Iverson MT, Phillips AG, Fibiger HC (1986) The effects of haloperidol on amphetamine- and methylphenidate-induced conditioned place preferences and locomotor activity. Psychopharmacology 90:247-252
31. Murphy D, Bailey K, Stone M, Wirshing WC (2008) Addictive potential of quetiapine. Am J Psychiatr 165:918. doi: 10.1176/appi.ajp.2008.08020277
32. Nikisch G, Baumann P, Kiebling B, Reinert M, Wiedemann G, Kehr J, Mathe AA, Piel M, Roesch F, Weidder H, Schneider P, Hertel A (2010) Relationship between dopamine D2 receptor occupancy, clinical response and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. J Psychiatr Res 44:754-759. doi: 10.1016/j.jpsychires.2010.02.004
33. Paparrigopoulos T, Karaiskos D, Liappas J (2008) Quetiapine: another drug with potential for misuse? A case report. J Clin Psychiatry 69:162-163
34. Pello S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-187
35. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC (2004) Intranasal quetiapine abuse. Am J Psychiatr 161:1718
36. Pifl C, Agneter E, Drobny H, Sitte HH, Singer EA (1999) Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 38:157-165
37. Pinta ER, Taylor RE (2007) Quetiapine addiction? Am J Psychiatr 164:174-175. doi: 10.1176/appi.ajp.164.1.174
38. Pisu C, Pira L, Pani L (2010) Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. Behav Pharmacol 21:649-653. doi: 10.1097/FBP.0b013e32833e7eab
39. Reeves RR, Brister JC (2007) Additional evidence of the abuse potential of quetiapine. South Med J 100:834-836
40. Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292
41. Schotte A, Janssen PFM, Commeren W, Luyten WHML, Gompel PV, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73
42. Spyraki C, Fibiger HC, Phillips AG (1982a) Cocaine-induced place preference conditioning: lack of effects of neuroleptics and 6-hydroxydopamine lesions. Brain Res 253:195-203
43. Spyraki C, Fibiger HC, Phillips AG (1982b) Dopaminergic substrates of amphetamine-induced place preference conditioning. Brain Res 253:185-193
44. Tada M, Shirakawa K, Matsuoka N (2004) Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effects and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology 176:94-100
45. Trent NL, Menard JL (2011) Infusions of neuropeptice Y into the lateral septum reduce anxiety-related behaviors in the rat. Pharmacol Biochem Behav 99:580-590. doi: 10.1016/j.pbb.2011.06.009
46. Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12:227-462
47. Uhl GR, Hall FS, Sora I (2002) Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 7:21-26
48. Wagner U, Segura-Torres P, Weiler T, Huston JP (1993) The tuberomammillary nucleus region as a reinforcement inhibiting substrate: facilitation of ipsihypothalamic self-stimulation by unilateral ibotenic acid lesions. Brain Res 613:269-274
49. Wang HN, Peng Y, Tan QR, Chen YC, Zhang RG, Qiao YT, Wang HH, Liu L, Kuang F, Wang BR, Zhang ZJ (2010) Quetiapine ameliorates anxiety-like behaviour and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder. Physiol Res 59:263-271
50. Waters BM, Joshi KG (2007) Intravenous quetiapine-cocaine use ("Q-ball"). Am J Psychiatr 164:173-174
51. Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzales-Maeso J, Hornung J, Sibille E, Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, Sealfon S, Hen R, Gingrich JA (2006) Cortical 5-HT2A receptor signaling modulates anxiety-like behaviours in mice. Science 313:536-540
52. White NM, Packard MG, Hiroi (1991) Place conditioning with dopamine D1 and D2 agonists injected peripherally or into nucleus accumbens. Psychopharmacology 103:271-276
53. Williams TP, Miller BD (2003) Pharmacologic management of anxiety disorders in children and adolescents. Curr Opin Paediatr 15:483-490
54. Zhornitsky S, Potvin S, Stip E, Rompre PP (2010) Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of D-amphetamine. Eur Neuropsychopharmacol 20:695-703. doi: 10.1016/j.euroneuro.2010.04.011